DOWN-REGULATION OF GENE EXPRESSION BY COLORECTAL ADMINISTRATION OF SYNTHETIC OLIGONUCLEOTIDES

Abstract: Disclosed is a method of down-regulating the expression of a gene in an animal, wherein an oligonucleotide complementary to the gene is colorectally administered to an animal. Also disclosed is a method for introducing an intact oligonucleotide into a mammal by colorectal administration, whereby the oligonucleotide is present in intact form in the systemic plasma of the mammal at least four hours following administration.

Description: DOW -REGUIATION OF GENE EXPRESSION BY COLORECTAL ADMINISTRATION OF SYNTHETIC OLIGONUCLEOTIDES BACKGROUND OF THE INVENTION The present invention relates to the control of gene expression. More particularly, this invention relates to the use of synthetic oligonucleotides to down-regulate the expression of a gene in an animal. The potential for the development of an antisense oligonucleotide therapeutic approach was first suggested in three articles published in 1977 and 1978. Paterson et al . { Proc. Natl. Acad. Sci. (USA) (1977) 74:4370-4374) discloses that cell-free translation of mRNA can be inhibited by the binding of an oligonucleotide complementary to the mRNA. Zamecnik et al. (Proc. Natl. Acad. Sci. (USA) (1978) 75:280- 284 and 285-288) discloses that a 13mer synthetic oligonucleotide that is complementary to a part of the Rous sarcoma virus (RSV) genome inhibits RSV replication in infected chicken fibroblasts and inhibits RSV-mediated transformation of primary chick fibroblasts into malignant sarcoma cells. These early indications that synthetic oligonucleotides can be used to inhibit virus propagation and neoplasia have been followed by the use of synthetic oligonucleotides to inhibit a wide variety of viruses, such as HIV (see, e.g., U.S. Patent No. 4,806,463); influenza (see, e.g., Leiter et al. (1990) (Proc. Natl. Acad. Sci. (USA) 87:3430-3434); vesicular stomatitis virus (see, e.g., Agris et al . (1986) Biochem. 25:6268-6275); herpes simplex (see, e.g., Gao et al . (1990) Antimicrob. Agents Chem. 34:808- 812); SV40 (see, e.g., Birg et al . (1990) (Nucleic Acids Res. 18:2901-2908); and human papilloma virus (see, e.g., Storey et al . (1991) (Nucleic Acids Res. 19:4109-4114). The use of synthetic oligonucleotides and their analogs as antiviral agents has recently been extensively reviewed by Agrawal ( Trends in Biotech. (1992) 10:152-158). In addition, synthetic oligonucleotides have been used to inhibit a variety of non-viral pathogens, as well as to selectively inhibit the expression of certain cellular genes. Thus, the utility of synthetic oligonucleotides as agents to inhibit virus propagation, propagation of non-viral, pathogens and selective expression of cellular genes has been well established. Improved oligonucleotides have more recently been developed that have greater efficacy in inhibiting such viruses, pathogens and selective gene expression. Some of these oligonucleotides having modifications in their internucleotide linkages have been shown to be more effective than their unmodified counterparts. For example, Agrawal et al. ( Proc. Natl. Acad. Sci. (USA) (1988) 85:7079-7083) teaches that oligonucleotide phosphorothioates and certain oligonucleotide phosphoramidates are more effective at inhibiting HIV-1 than conventional phosphodiester-linked oligodeoxynucleotides . Agrawal et al . (Proc. Natl. Acad. Sci. (USA) (1989) 86:7790- 7794) discloses the advantage of oligonucleotide phosphorothioates in inhibiting HIV-1 in early and chronically infected cells. In addition, chimeric oligonucleotides having more than one type of internucleotide linkage within the oligonucleotide have been developed. Pederson et al. (U.S. Patent Nos. 5,149,797 and 5,220,007 discloses chimeric oligonucleotides having an oligonucleotide phosphodiester or oligonucleotide phosphorothioate core sequence flanked by nucleotide methylphosphonates or phosphoramidates . Furdon et al. (Nucleic Acids Res. (1989) 17:9193-9204) discloses chimeric oligonucleotides having regions of oligonucleotide phosphodiesters in addition to either oligonucleotide phosphorothioate or methylphosphonate regions. Quartin et al . (Nucleic Acids Res. (1989) 17:7523-7562) discloses chimeric oligonucleotides having regions of oligonucleotide phosphodiesters and oligonucleotide methylphosphonates. Inoue et al . ( FEBS Lett. (1987) 215:237-250) discloses chimeric oligonucleotides having regions of deoxyribonucleotides and 2 ' -O- methyl-ribonucleotides . Many of these modified oligonucleotides have contributed to improving the potential efficacy of the antisense oligonucleotide therapeutic approach. However, certain deficiencies remain in the known oligonucleotides, and these deficiencies can limit the effectiveness of such oligonucleotides as therapeutic agents. For example, Wickstrom (J. Biochem. Biophys. Meth. (1986) 13:97-102) teaches that oligonucleotide phosphodiesters are susceptible to nuclease-mediated degradation, thereby limiting their bioavailability in vivo . Agrawal et al . (Proc. Natl. Acad. Sci. (USA) (1990) 87:1401-1405) teaches that oligonucleotide phosphoramidates or methylphosphonates when hybridized to RNA do not activate RNase H, the activation of which can be important to the function of antisense oligonucleotides. Thus, a need for methods of controlling gene expression exists which uses oligonucleotides with improved therapeutic characteristics . Several reports have been published on the development of phosphorothioate- linked oligonucleotides as potential anti-AIDΞ therapeutic agents. Although extensive studies on chemical and molecular mechanisms of oligonucleotides have demonstrated the potential value of this novel therapeutic strategy, little is known about the pharmacokinetics and metabolism of these compounds in vivo . Several preliminary studies on this topic have been published. Agrawal et al . (Proc. Natl. Acad. Sci. (USA) (1991) 88:7595-7599) describes the intravenously and intraperitoneally administration to mice of a 20mer phosphorothioate linked- oligonucleotide . In this study, approximately 30% of the administered dose was excreted in the urine over the first 24 hours with accumulation preferentially in the liver and kidney. Plasma half-lives ranged from about 1 hour t 1/2α ) and 40 hours (t 1/2p ), respectively. Similar results have been reported in subsequent studies (Iversen (1991) Anti-Cancer Drug Design 6 : 531-538 ; Iversen ( 1994 ) Antisense Res. Devel. 4:43-52; and Sands (1994) Mol. Pharm. 45:932- 943) . However, stability problems may exist when oligonucleotides are administered intravenously and intraperitoneally . More recent studies have demonstrated that two hybrid oligonucleotides which are two end-protected [ 35 S] -radiolabelled analogs of a 25mer oligonucleotide phosphorothioate, one containing segments of 2 - ' O-methyloligoribonucleotide phosphorothioates at both 3'- and 5 ' -termini (MBO 1) and another containing methyl phosphonate linkages at both 3 ' - and 5 ' -termini (MBO 2) exhibited enterohepatic circulation in rats after i.v. bolus administration, with a significantly better in vivo stability than the oligonucleotide phosphorothioate (Zhang et al . (1995) Biochem . Pharmacol . 49:929-939; Zhang et al . (1995) Biochem . Pharmacol . 50:571-576; and Zhang et al. (1996) J " . Pharm. Exp . Ther . 278 :971-979) . Hybrid oligonucleotides have also been administered orally to rats with little degradation (Zhang et al. (1995) Biochem. Pharm . 50:545-556). However, there still remains a need to develop more effective therapeutic methods of down- regulating the expression of genes which can be easily manipulated to fit the animal and condition to be treated, and the gene to be targeted. Preferably, these methods should be simple, painless, and precise in effecting the target gene. SUMMARY OF THE INVENTION It has been discovered that certain end- modified oligonucleotides are relatively stable in vivo following colorectal administration to an animal, and that these molecules are successfully absorbed from the intestinal tract and distributed to various body tissues with little degradation. Thus, this form of administration bypasses the complications which may be experienced during oral, intravenous and other modes of in vivo administration. This discovery has been exploited to develop the present invention, which is a method of down-regulating the expression of a gene in an animal . This method is also a means of examining the function of various genes in an animal, including those essential to animal development. Presently, gene function can only be examined by the arduous task of making a "knock out" animal such as a mouse. This task is difficult, time-consuming and cannot be accomplished for genes essential to animal development since the "knock out" would produce a lethal phenotype . The present invention overcomes the shortcomings of this model. In the method of the invention, a pharmaceutical formulation containing an oligonucleotide complementary to the targeted gene is colorectally administered in a pharmaceutically acceptable carrier to the animal harboring the gene . The oligonucleotide inhibits the expression of the gene, thereby down-regulating its expression. For purposes of the invention, the term "animal" is meant to encompass humans as well as other mammals, as well as reptiles amphibians, and insects. The term "colorectal administration" or "rectal administration" or "colorectally administered" refers to the provision of the pharmaceutical formulation of the invention to any part of the large intestine via surgical implantation, anal administration, or any other mode of placement therein. The oligonucleotide being administered has non- phosphodiester linkages. As used herein, the term "oligonucleotide" is meant to include polymers of two or more nucleotides or nucleotide analogs connected together via 5 ' to 3 ' internucleotide linkages which may include any linkages that are known in the antisense art . Such molecules have a 3 ' terminus and a 5 ' terminus . The term "non-phosphodies ter-linked oligonucleotide" as used herein is an oligonucleotide in which all of its nucleotides are covalently linked via a synthetic linkage, i.e., a linkage other than a phosphodiester between the 5 ' end of one nucleotide and the 3 ' end of another nucleotide in which the 5 ' nucleotide phosphate has been replaced with any number of chemical groups . Preferable synthetic linkages include alkylphosphonates, phosphorothioates, phosphorodithioates , alkylphosphonothioates , phosphoramidates, phosphoramidites, phosphate esters, carbamates, carbonates, phosphate triesters, acetamidate, and carboxymethyl esters. In one embodiment of the invention, the all of the nucleotides of the oligonucleotide comprises are linked via phosphorothioate and/or phosphorodithioate linkages, and in one particular embodiment, the nucleotides are all phosphorothioate linked. In some embodiments of the invention, the oligonucleotides administered are further modified. As used herein, the term "modified oligonucleotide" encompasses oligonucleotides with modified nucleic acid(s), base(s), and/or sugar (s) other than those found in nature. For example, a 3', 5 ' -substituted oligonucleotide is an oligonucleotide having a sugar which, at both its 3 ' and 5 ' positions is attached to a chemical group other than a hydroxyl group (at its 3 ' position) and other than a phosphate group (at its 5' position) . A modified oligonucleotide may also be one with added substituents such as diamines, cholestryl, or other lipophilic groups, or a capped species. In addition, unoxidized or partially oxidized oligonucleotides having a substitution in one nonbridging oxygen per nucleotide in the molecule are also considered to be modified oligonucleotides. Also considered as modified oligonucleotides are oligonucleotides having nuclease resistance- conferring bulky substituents at their 3 ' and/or 5 ' end(s) and/or various other structural modifications not found in vivo without human intervention are also considered herein as modified. In one preferred embodiment of the invention, the oligonucleotide administered includes at least one 2 ' -substituted ribonucleotide at its 3 ' terminus or 5 ' terminus . For purposes of the invention, the term "2'- substituted oligonucleotide" refers to an oligonucleotide having a sugar attached to a chemical group other that a hydroxyl group at its 2 ' position. The 2 ' -OH of the ribose molecule can be substituted with -O-lower alkyl containing 1-6 carbon atoms, aryl or substituted aryl or allyl having 2-6 carbon atoms, e.g., 2'-0-allyl, 2 ' -O- aryl, 2 ' -O-alkyl (such as a 2 ' -O-methyl) , 2 '-halo, or 2' -amino, but not with 2 ' -H, wherein allyl, aryl, or alkyl groups may be unsubstituted or substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl or amino groups . In some embodiments, all but four or five nucleotides at the 5 ' or 3 ' terminus of the oligonucleotide are 2 ' -substituted ribonucleotides . In other embodiments, the oligonucleotide has at least one 2 ' -substituted ribonucleotide at both its 3' and 5' termini, and in yet other embodiments, the oligonucleotide is composed of 2 ' -substituted ribonucleotides in all positions with the exception of at least four or five contiguous deoxyribonucleotide nucleotides in any interior position. Another aspect of the invention includes the administration of an oligonucleotide composed of nucleotides that are all 2 ' -substituted ribonucleotides . Particular embodiments include oligonucleotides having a 2 ' -O-alkyl-ribonucleotide such as a 2 ' -0 methyl. In other embodiments, the oligonucleotide useful in the method of the invention has at least one methylphosphonate deoxynucleotide at its 3' and 5' termini. In some preferred embodiments, the oligonucleotide has at least two methylphosphonate deoxynucleotides at the 3 ' terminus and at the 5 ' terminus . In particular embodiments, this oligonucleotide further comprises phosphorothioate internucleotide linkages In another embodiment of the invention, the oligonucleotide administered has at least one deoxyribonucleotide, and in a preferred embodiment, the oligonucleotide has at least four or five contiguous deoxyribonucleotides capable of activating RNase H. The oligonucleotide administered is complementary to a gene of a virus, pathogenic organism, or a cellular gene in some embodiments of the invention. In some embodiments, the oligonucleotide is complementary to a gene of a virus involved in AIDS, oral or genital herpes, papilloma warts, influenza, foot and mouth disease, yellow fever, chicken pox, shingles, adult T-cell leukemia, Burkitt's lymphoma, nasopharyngeal carcinoma, or hepatitis. In one particular embodiment, the oligonucleotide is complementary to an HIV gene and includes about 15 to 26 nucleotides linked by phosphorothioate internucleotide linkages, at least one of the nucleotides at the 3 ' terminus being a 2 ' -substituted ribonucleotide, and at least four contiguous deoxyribonucleotides. In another embodiment, the oligonucleotide is complementary to a gene encoding a protein in associated with Alzheimer's disease. In yet other embodiments, the oligonucleotide is complementary to a gene encoding a protein expressed in a parasite that causes a parasitic disease such as amebiasis, Chagas ' disease, toxoplasmosis , pneumocytosis , giardiasis, cryptoporidiosis , trichomoniasis, malaria, ascariasis, filariasis, trichinosis, or schistosomiasis infections. In another aspect, the invention provides a method for introducing an intact oligonucleotide into an animal. In this method an end-protected oligonucleotide is colorectally administered to the animal, whereby the oligonucleotide is present in intact form in the systemic plasma of the mammal at least about four hours following administration. As used herein, the term "intact form" refers to an administered oligonucleotide which is relatively undegraded or undigested. This oligonucleotide is about 5 to 50, preferably about 12 to 35, and most preferably about 15 to 25 nucleotides in length. An "end-protected oligonucleotide" is used herein to describe an oligonucleotide which has been modified at its 5 ' and/or 3 ' terminus such that it is less susceptible to enzymatic digestion by exonucleases than oligonucleotides which are not end-protected. Any modification to the terminus or termini of an administered oligonucleotide which results in protection from exonucleases but which does not greatly inhibit the ability of an oligonucleotide to hybridize to a complementary nucleotide sequence are meant to be encompassed by this term. In one embodiment, an end-protected oligonucleotide comprises at least one 2 ' -O-methyl- ribonucleotide or methylphosphonate deoxynucleotide at each terminus . In another embodiment the end- protected oligonucleotide comprises at least two 2 ' - O-methyl-ribonucleotides or methylphosphonate deoxynucleotides at each terminus . In yet another embodiment, the end-protected oligonucleotide comprises at least two 2 ' -O-methyl ribonucleotides at each terminus and further comprises phosphorothioate internucleoside linkages. In still another embodiment, the end-protected oligonucleotide comprises at least two methylphosphonate deoxynucleotides at each terminus and further comprises phosphorothioate internucleotide linkages. In some embodiments, the end-protected oligonucleotide comprises four methylphosphonate deoxynucleotides at each terminus. BRIEF DESCRIPTION OF THE DRAWINGS The foregoing and other objects of the present invention, the various features thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which: FIG. 1 is a diagrammatic representation of the enterohepatic circulation of oligonucleotides and the delivery of such oligonucleotides through the gastrointestinal tract; FIG. 2 is a schematic representation of the chemical structure of PS-oligonucleotide and end- modified MBO 1 (SEQ ID NO: 11) and MBO 2 (SEQ ID NO: 16) ; FIG. 3A is an HPLC profile of radiolabelled MBO 1 standard; FIG. 3B is an HPLC profile of radioactivity in the contents of the large intestine of a rat 4 hours after administration of radiolabelled MBO 1 to the large intestine of the rat; FIG. 3C is an HPLC profile of radioactivity in the large intestine of a rat 4 hours after administration of radiolabelled MBO 1 to the large intestine of the rat; FIG. 4 is a graphic representation of the concentration of MBO 1 equivalents in plasma at various times after administration of various dosages of MBO 1 to the large intestine of a rat; FIG. 5 is a graphic representation of the concentration of MBO 1 equivalents in selected tissues 4 hours after administration of various dosages of MBO 1 to the large intestine of a rat; FIG. 6A is an HPLC profile of radioactivity in the plasma of a rat 4 hours after administration of radiolabelled MBO 1 to the large intestine of the rat; FIG. 6B is an HPLC profile of radioactivity in the liver of a rat 4 hours after administration of radiolabelled MBO 1 to the large intestine of the rat ; and FIG. 6C is an HPLC profile of radioactivity in the kidney of a rat 4 hours after administration of radiolabelled MBO 1 to the large intestine of the rat. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued U.S. patents, allowed patent applications, and articles cited herein are hereby incorporated by reference . This invention provides a method of down- regulating the expression of a gene in an animal by the colorectal administration of an oligonucleotide whose nucleotide sequence is complementary to the targeted gene. This invention also provides a method for introducing an intact oligonucleotide into a mammal by colorectal administration. It is known that a synthetic oligonucleotide, called an "antisense oligonucleotide, " can bind to a target single-stranded nucleic acid molecule according to the Watson-Crick or the Hoogsteen rule of base pairing, and in doing so, disrupt the function of the target by one of several mechanisms: by preventing the binding of factors required for normal transcription, splicing, or translation; by triggering the enzymatic destruction of mRNA by RNase H if a contiguous region of deoxyribonucleotides exists in the oligonucleotide, and/or by destroying the target via reactive groups attached directly to the antisense oligonucleotide. Thus, because of the properties described above, such oligonucleotides are useful therapeutically by their ability to control or down- regulate the expression of a particular gene in an animal, according to the method of the present invention. The pharmacokinetics and factors affecting gastrointestinal absorption of oligonucleotides, including colorectal absorption, are summarized in the scheme presented in FIG. 1. Briefly, when oligonucleotides are administered orally, they may be stable in the stomach contents and whether they are absorbed through the stomach wall is not clear. When the administered oligonucleotides move into small intestines, extensive degradation of PS-oligonucleotides and some degradation of MBO ' s may occur. Intact oligonucleotides (and maybe degradative forms) are absorbed through portal venous blood and enter the liver. The absorbed oligonucleotides may undergo metabolism in the liver (the first-pass effect) and enter the systemic circulation. Oligonucleotides and their metabolites are excreted into bile and enter the intestinal lumen and reenter the enterohepatic circulation. Oligonucleotides in the systemic circulation are distributed into various tissues and excreted into urine as seen following i.v. administration. When orally administered oligonucleotides move into the large intestine, most PS-oligonucleotides and some MBO ' S may be present as degradation products. In general, oligonucleotides absorbed through the upper portion of the large intestine enter the liver, and oligonucleotides absorbed through the lower portion of the large intestine directly enter the systemic circulation. The latter are not metabolized in the liver and the first-pass effect of the liver is avoided. Colorectal administration of oligonucleotides takes the advantage of this opportunity. When oligonucleotides are administered into the rectum, most absorbed oligonucleotides enter the systemic circulation. Colorectal administration employs the pharmacokinetics of phosphorothioates as well as MBO's, making PS a viable choice for gastrointestinal administration. In general, the following factors are important to the development of rectal oligonucleotides therapeutics: 1) stability of oligonucleotides in the gastrointestinal tract; 2) duration of the retention of oligonucleotides in the gastrointestinal tract; 3) the structure and physical and biochemical properties of oligonucleotides, e.g., charges; 4) the first-pass effect of the liver; 5) diet and host status of the gastrointestinal and hepatic functions; and 6) formulations. The advantages of delivery of oligonucleotides through rectal administration are obvious . The slow but continuous release of oligonucleotides into the systemic circulation may increase the uptake of target tissues. In addition, it avoids the high plasma concentrations associated with i . v. injection and reduces the risk of side effects resulting from these high concentrations. -Ii The oligonucleotides which are colorectally administered according to the method of invention are at least 6 nucleotides in length, but are preferably 6 to 50 nucleotides long, with 15 to 30mers being the most common. They are composed of deoxyribonucleotides, ribonucleotides, or a combination of both, with the 5 ' end of one nucleotide and the 3 ' end of another nucleotide being covalently linked by phosphodiester bonds. The oligonucleotides used in the claimed method may also be modified in a number of ways without compromising their ability to hybridize to the target nucleic acid. Such modifications include, for example, non-phosphodiester internucleotide linkages including alkylphosphonates , phosphorothioates, phosphorodithioates, alkylphosphonothioates , alkylphosphonates , phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. Particularly useful oligonucleotides are linked with phosphorothioate and/or phosphorodithioate internucleoside linkages. Preferably, oligonucleotides according to the invention ranging from about 6 to about 50 nucleotides in length, and most preferably from about 12 to about 30 nucleotides in length, will have from 11 to 29 non-phosphodiester internucleotide linkages. Other useful modifications include those which are internal or at the end(s) of the oligonucleotide molecule and include additions to the molecule of the internucleoside phosphate linkages, such as cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the viral genome. Examples of such modified oligonucleotides include oligonucleotides with a modified base and/or sugar such as arabinose instead of ribose, or a 3 ' , 5'- substituted oligonucleotide having a sugar which, at both its 3 ' and 5 ' positions is attached to a chemical group other than a hydroxyl group (at its 3 ' position) and other than a phosphate group (at its 5 ' position) . Other modified oligonucleotides are capped with a nuclease resistance-conferring bulky substituent at their 3' and/or 5' end(s), or have a substitution in one nonbridging oxygen per nucleotide. Such modifications can be at some or all of the internucleoside linkages, as well as at either or both ends of the oligonucleotide and/or in the interior of the molecule. Oligonucleotides which are self-stabilized are also considered to be modified oligonucleotides useful in the methods of the invention (Tang et al . (1993) Nucleic Acids Res . 20:2729-2735). These oligonucleotides comprise two regions: a target hybridizing region; and a self- complementary region having an oligonucleotide sequence complementary to a nucleic acid sequence that is within the self-stabilized oligonucleotide. Modified and unmodified oligonucleotides can be prepared according to known methods which can be carried out manually or by an automated synthesizer as described by Brown (A Brief History of Oligonucleotide Synthesis. Protocols for Oligonucleotides and Analogs, Methods in Molecular Biology (1994) 20:1-8). See also, Sonveaux "Protecting Groups in Oligonucleotides Synthesis" in Agrawal (1994) Methods in Molecular Biology 26:1-72; Agrawal et al . (1992) Trends Biotechnol. 10:152-158; Uhlmann et al . (1990) Chem. Rev. 90:543-583; and (1987) Tetrahedron. Lett. 28 : (31) : 3539-3542 ) . One preferred oligonucleotide useful in the method of the invention are hybrid oligonucleotides containing both deoxyribonucleotides and at least one 2' substituted ribonucleotide. For purposes of the invention, the term "2 ' -substituted" means substitution of the 2 ' -OH of the ribose molecule with, e.g., 2'-0-allyl, 2'-0-alkyl, 2'-halo, or 2 ' - amino, but not with 2 ' -H, wherein allyl, aryl, or alkyl groups may be unsubstituted or substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl or amino groups. Other preferred oligonucleotides useful in the method of the invention have at least one or all phosphorothioate internucleotide linkages . The hybrid DNA/RNA oligonucleotides useful in the method of the invention resist nucleolytic degradation, form stable duplexes with RNA or DNA, and preferably activate RNase H when hybridized with RNA. They may additionally include at least one unsubstituted ribonucleotide. For example, an oligonucleotide useful in the method of the invention may contain all deoxyribonucleotides with the exception of one 2 ' substituted ribonucleotide at the 3' terminus of the oligonucleotide. Alternatively, the oligonucleotide may have at least one substituted ribonucleotide at both its 3 ' and 5 ' termini . One preferred class of oligonucleotides useful in the method of the invention contains at least four or more deoxyribonucleotides in a contiguous block, so as to provide an activating segment for RNase H. In certain cases, more than one such activating segment will be present at any location within the oligonucleotide. There may be a majority of deoxyribonucleotides in oligonucleotides useful in the method of the invention. In fact, such oligonucleotides may have as many as all but one, two, three, or four nucleotide (s) being deoxyribonucleotides. Thus, in a preferred oligonucleotide having from about 6 to about 50 nucleotides or most preferably from about 12 to about 30 nucleotides, the number of deoxyribonucleotides present ranges from 1 to about 29. Other useful oligonucleotides may consist particularly of at least one, two, four, or more 2 ' -substituted ribonucleotide (s) at one or both termini of the oligonucleotide. Some oligonucleotides useful in the method of the invention have only 2 ' -substituted ribonucleotides . The 2' substituted ribonucleotide (s) in the oligonucleotide may contain at the 2 ' position of the ribose, a -O-lower alkyl containing 1-6 carbon atoms, aryl or substituted aryl or allyl having 2-6 carbon atoms e.g., 2'-0-allyl, 2'-0-aryl, 2 ' -O- alkyl, 2 '-halo, or 2 '-amino, but not with 2'-H, wherein allyl, aryl, or alkyl groups may be unsubstituted or substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl or amino groups. Useful substituted ribonucleotides are 2'- 0-alkyls such as 2'-0-methyl. TABLE 1 lists some representative species of oligonucleotides which are useful in the method of the invention. 2 ' -substituted nucleotides are underscored, and nucleotide methylphosphonates are bolded. TABLE 1 NO. OLIGONUCLEOTIDE SEO ID NO: 1 CTCTCGCACCCATCTCTCTCCTTCU 1 2 CTCTCGCACCCATCTCTCTCCTUCU 2 3 CTCTCGCACCCATCTCTCTCCUUCU 3 4 CTCTCGCACCCATCTCUCUCCUUCU 4 5 CTCTCGCACCCAUCUCUCUCCUUCU 5 6 CTCTCGCACCCAUCUCUCUCCUUCU 5 7 CTCTCGCACCCAUCUCUCUCCUUCU 5 8 CUCUCGCACCCAUCUCUCUCCUUCU 6 9 CTCTCGCACCCATCTCTCTCCTTCU 7 10 CUCTCGCACCCATCTCTCTCCTTCU 7 11 CUCUCGCACCCATCTCTCTCCUUCU 8 12 CUCUCGCACCCATCTCUCUCCUUCU 9 13 CUCUCGCACCCAUCUCUCUCCUUCU 10 14 CUCUCGCACCCATCTCTCUCCUUCU 11 15 CTCTCGCACCCAUCUCUCUCCUUCU 5 16 CUCUCGCACCCAUCTCTCTCCUUCU 12 17 CUCUCGCACCCATCTCTCTCCUUCU 13 18 CUCTCGCACCCAUCUCUCUCCUUCU 14 19 CUCTCGCACCCATCTCTCUCCUUCU 15 MBO 1 CUCUCGCACCCATCTCTCTCCUUCU 11 MBO 2 CTCTCGCACCCATCTCTCTCCTTCT 16 20 CTCTCGCACCCATCTCTCTCCTTCT 17 21 CUCTCGCACCCATCTCTCTCCTTCT 18 22 CUCUCGCACCCATCTCTCTCCTTCT 19 23 CUCUCGCACCCATCTCTCTCCTTCT 19 24 CUCUCGCACCCAUCUCTCTCCTTCT 20 25 CUCUCGCACCCAUCUCUCUCCTTCT 21 26 CTCTCGCACCCATCTCTCTCCTTCT 17 The oligonucleotides used in the method of the invention are effective in inhibiting the expression of various genes in viruses, pathogenic organisms, or in inhibiting the expression of cellular genes . The ability to inhibit such agents is clearly important to the treatment of a variety of disease states. Thus, oligonucleotides according to the method of the invention have a nucleotide sequence which is complementary to a nucleic acid sequence that is from a virus, a pathogenic organism or a cellular gene. For purposes of the invention, the term "oligonucleotide sequence that is complementary to a nucleic acid sequence" is intended to mean an oligonucleotide sequence that binds to the target nucleic acid sequence under physiological conditions, e.g., by Watson-Crick base pairing (interaction between oligonucleotide and single- stranded nucleic acid, such as RNA or cDNA) or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other means including in the case of a oligonucleotide binding to RNA, pseudoknot formation. Such binding (by Watson Crick base pairing) under physiological conditions is measured as a practical matter by observing interference with the function of the nucleic acid sequence. The nucleic acid to which the oligonucleotide is complementary may be genomic DNA, RNA, mRNA or cDNA. The sequence of the nucleic acid to which an oligonucleotide according to the invention is complementary will vary, depending upon the gene to be down-regulated. In some cases, the target gene or nucleic acid sequence will be a virus nucleic acid sequence. The use of antisense oligonucleotides to inhibit various viruses is well known (reviewed in Agrawal (1992) Trends in Biotech. 10:152-158) . Viral nucleic acid sequences that are complementary to effective antisense oligonucleotides have been described for many viruses, including human immunodeficiency virus type 1 (HIV-1) (U.S. Patent No. 4,806,463), herpes simplex virus (U.S. Patent No. 4,689,320), influenza virus (U.S. Patent No. 5,194,428), and human papilloma virus (Storey et al . (1991) Nucleic Acids Res. 19:4109-4114 ) . Sequences complementary to any of these nucleic acid sequences can be used for oligonucleotides according to the invention, as can be oligonucleotide sequences complementary to nucleic acid sequences from any other virus. Additional viruses that have known nucleic acid sequences against which antisense oligonucleotides can be prepared include, but are not limited to, foot and mouth disease virus (see, Robertson et al . (1985) J. Virol. 54:651; Harris et al . (1980) Virol. 36:659), yellow fever virus (see Rice et al . (1985) Science 229:726), varicella-zoster virus (see, Davison and Scott (1986) J. Gen. Virol. 67:2279), Epstein-Barr virus, cytomegalovirus, respiratory syncytial virus (RSV) , and cucumber mosaic virus (see Richards et al . (1978) Virol. 89:395) . For example, an oligonucleotide has been designed which is complementary to a portion of the HIV-1 gene, and as such, has significant anti-HIV effects (Agrawal (1992) Antisense Res. Development 2:261- 266) . The target of this oligonucleotide has been found to be conserved among various HIV-1 isolates. It is 56% G + C rich, water soluble, and relatively stable under physiological conditions. This oligonucleotide binds to a complementary RNA target under physiological conditions, with the T of the duplex approximately being 56°C. The antiviral activity of this oligonucleotide has been tested in several models, including acutely and chronically infected CEM cells, long-term cultures mimicking in vivo conditions, human peripheral blood lymphocytes and macrophages, and isolates from HIV-1 infected patients (Lisziewicz et al . (Proc. Natl. Acad. Sci. (USA) (1992) 89:11209-11213); Lisziewicz et al . (Proc. Natl. Acad. Sci. (USA) (1993) 90:3860-3864); Lisziewicz et al . (Proc. Natl. Acad. Sci. (USA) (1994) 91:7942-7946) ; Agrawal et al. (J. Ther. Biotech) in press) . The oligonucleotides according to the invention alternatively can have an oligonucleotide sequence complementary to a nucleic acid sequence of a pathogenic organism. The nucleic acid sequences of many pathogenic organisms have been described, including the malaria organism, Plasmodium falciparum , and many pathogenic bacteria. Oligonucleotide sequences complementary to nucleic acid sequences from any such pathogenic organism can be used in oligonucleotides according to the invention. Examples of pathogenic eucaryotes having known nucleic acid sequences against which antisense oligonucleotides can be prepared include Trypanosom abrucei gambiense and Leishmania (See Campbell et al . , Nature 311:350 (1984)), Fasciola hepatica (See Zurita et al. , Proc. Natl. Acad. Sci. USA 84:2340 (1987) . Antifungal oligonucleotides can be prepared using a target hybridizing region having an oligonucleotide sequence that is complementary to a nucleic acid sequence from, e.g., the chitin synthetase gene, and antibacterial oligonucleotides can be prepared using, e.g., the alanine racemase gene . Among fungal diseases that may be treatable by the method of treatment according to the invention are candidiasis, histoplasmosis, cryptococcocis, blastomycosis, aspergillosis, sporotrichosis, chromomycosis, dermatophytosis, and coccidioidomycosis . The method might also be used to treat rickettsial diseases (e.g., typhus, Rocky Mountain spotted fever) , as well as sexually transmitted diseases caused by Chlamydia trachomatis or Lymphogranuloma venereum. A variety of parasitic diseases may be treated by the method according to the invention, including amebiasis, Chagas ' disease, toxoplasmosis , pneumocystosis , giardiasis, cryptosporidiosis, trichomoniasis, and Pneumocystis carini pneumonia; also worm (helminthic) diseases such as ascariasis, filariasis, trichinosis, schistosomiasis and nematode or cestode infections . Malaria may be treated by the method of treatment of the invention regardless of whether it is caused by P. falcip arum, P. vivas, P. orale, or P. malariae. The infectious diseases identified above may all be treated by the method of treatment according to the invention because the infectious agents for these diseases are known and thus oligonucleotides according to the invention can be prepared, having oligonucleotide sequence that is complementary to a nucleic acid sequence that is an essential nucleic acid sequence for the propagation of the infectious agent, such as an essential gene. Other disease states or conditions that may be treatable by the method according to the invention are those which result from an abnormal expression or product of a cellular gene . These conditions may be treated by administration of oligonucleotides according to the invention, and have been discussed earlier in this disclosure. Other oligonucleotides according to the invention can have a nucleotide sequence complementary to a cellular gene or gene transcript, the abnormal expression or product of which results in a disease state. The nucleic acid sequences of several such cellular genes have been described, including prion protein (Stahl et al . (1991) FASEB J.5:2799-2807), the amyloid-like protein associated with Alzheimer's disease (U.S. Patent No. 5,015,570), and various well-known oncogenes and proto-oncogenes, such as c-myb, c-myc, c-abl, and n- ras . In addition, oligonucleotides that inhibit the synthesis of structural proteins or enzymes involved largely or exclusively in spermatogenesis, sperm motility, the binding of the sperm to the egg or any other step affecting sperm viability may be used as contraceptives. Similarly, contraceptives for women may be oligonucleotides that inhibit proteins or enzymes involved in ovulation, fertilization, implantation or in the biosynthesis of hormones involved in those processes. Hypertension may be controlled by oligonucleotides that down-regulate the synthesis of angiotensin converting enzyme or related enzymes in the renin/angiotensin system. Platelet aggregation may be controlled by suppression of the synthesis of enzymes necessary for the synthesis of thromboxane A2 for use in myocardial and cerebral circulatory disorders, infarcts, arteriosclerosis, embolism and thrombosis. Deposition of cholesterol in arterial wall may be inhibited by suppression of the synthesis of fatty acid co-enzyme A: cholesterol acyl transferase in arteriosclerosis. Inhibition of the synthesis of cholinephosphotransferase may be useful in hypolipidemia . There are numerous neural disorders in which hybridization arrest may be used to reduce or eliminate adverse effects of the disorder. For example, suppression of the synthesis of monoamine oxidase may be used in Parkinson's disease. Suppression of catechol o-methyl transferase may be used to treat depression; and suppression of indole N-methyl transferase may be used in treating schizophrenia . Suppression of selected enzymes in the arachidonic acid cascade which leads to prostaglandins and leukotrienes may be useful in the control of platelet aggregation, allergy, inflammation, pain and asthma. Suppression of the protein expressed by the multidrug resistance (mdr-1 ) gene, which can be responsible for development of resistance of tumors to a variety of anti-cancer drugs and is a major impediment in chemotherapy may prove to be beneficial in the treatment of cancer. Oligonucleotide sequences complementary to nucleic acid sequences from any of these genes can be used for oligonucleotides according to the invention, as can be oligonucleotide sequences complementary to any other cellular gene transcript, the abnormal expression or product of which results in a disease state. The oligonucleotides described herein are administered colorectally to the animal subject in the form of therapeutic pharmaceutical formulations that are effective for treating virus infection, infections by pathogenic organisms, or disease or disorder resulting from abnormal gene expression or from the expression of an abnormal gene product and are suitable for colorectal delivery. In some aspects of the method according to the invention, the oligonucleotides are administered in conjunction with other therapeutic agents, e.g., AZT in the case of AIDS. The therapeutic pharmaceutical formulation of the invention includes an oligonucleotide as described above and a physiologically acceptable carrier, such as an inert diluent or an assimilable carrier with which the oligonucleotide is administered. Suitable formulations that include pharmaceutically acceptable excipients for introducing compounds to the bloodstream by other than injection routes can be found in Remington's Pharmaceutical Sciences (18th ed. ) (Genarro, ed. (1990) Mack Publishing Co., Easton, PA). The pharmaceutical formulation that may be introduced in a solid, semi-solid, suspension, or emulsion form and may be compounded with any number of well-known, pharmaceutically acceptable additives . The oligonucleotide and other ingredients may be enclosed in a hard or soft shell gelatin capsule, contained within gels or creams, or compressed into suppositories, and the like. Sustained release delivery systems and/or coatings for colorectally administered dosage forms are also contemplated, such as those described in U.S. Patent Nos. 4,704,295, 4,556,552, 4,309,404, and 4,309,406 for oral administration. As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical formulation or method that is sufficient to show a meaningful subject or patient benefit, i.e., healing of disease conditions characterized by the disease being treated and/or an increase in rate of healing of such conditions, a reduction in the expression of proteins or cells which cause or characterize the disease or disorder being treated (e.g., in the case of a virus, a decrease in virus load over baseline under disease conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. The therapeutically effective amount of synthetic oligonucleotide colorectally administered in the method of the invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patent has undergone. Ultimately, the attending physician will decide the amount of synthetic oligonucleotide with which to treat each individual patient. Initially, the attending physician may administer low doses of the synthetic oligonucleotide and observe the patient's response. Larger doses of synthetic oligonucleotide may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the dosages of the pharmaceutical compositions administered in the method of the present invention should contain about 0.1 to 100.0 mg/kg body weight per day, preferably 0.1 to 75.0 mg/kg body weight per day, more preferably, 1.0 to 50.0 mg/kg body weight per day, even more preferably, 1 to 25 mg/kg body weight per day, and even more preferably, 1 to 10 or 1 to 5.0 mg/kg body weight per day. The oligonucleotide is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 μM to about 100 μM. Preferably, the concentration of oligonucleotide at the site of aberrant gene expression should be from about 0.01 μM to about 50 μM, more preferably, from about 0.01 μM to about 10 μM, and most preferably from about 0.05 μM to about 5 μM. However, for localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. It may be desirable to administer simultaneously or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention when individual as a single treatment episode . It will be appreciated that the unit content of active ingredient or ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units (such as suppositories, gels, or creams, or combinations thereof) . In fact, multi-dosing (once a day) has been shown to significantly increase the plasma and tissue concentrations of MBO's (data not shown). The oligonucleotides according to the invention are administered to the animal in a therapeutically effective manner. A "therapeutically effective manner" refers to a route, duration, and frequency of administration of the pharmaceutical formulation which ultimately results in meaningful patient benefit, as described above. In some embodiments of the invention, the pharmaceutical formulation is administered in bolus, continuous, intermittent, or continuous amounts, followed by intermittent regimens . The pharmaceutical formulation can be administered in bolus, continuous, or intermittent dosages, or in a combination of continuous and intermittent dosages, as determined by the physician and the degree and/or stage of illness of the patient. The duration of therapy using the pharmaceutical composition of the present invention will vary, depending on the unique characteristics of the oligonucleotide and the particular therapeutic effect to be achieved, the limitations inherent in the art of preparing such a therapeutic formulation for the treatment of humans, the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention. To determine the stability of antisense oligonucleotides according to the invention in the intestinal tract, and to determine their ability to be absorbed through the intestinal wall, two r adioac t ive ly labelled, end-modified oligonucleotides, MBO 1 (SEQ ID NO: 11) and MBO 2 (SEQ ID NO: 16), and one phosphorothioate oligonucleotide (SEQ ID NO: 16) were administered to the large intestine of rats. The chemical structure of these oligonucleotides is shown in FIG. 2. The tissue distribution of these oligonucleotides and their stability was then measured. MBO 1 was stable in the large intestine as analyzed by HPLC and PAGE for up to 4 hr following administration, with minimal degradation being observed (FIGS. 3B and 4). Gel electrophoresis revealed that the majority of extracted radioactivity in large intestine and its contents was intact oligonucleotide (data not shown) . The absorption of MBO 1 was examined at doses of 3.3, 10, 30, and 90 mg/kg. Oligonucleotide-derived radioactivity was detectable in various tissues following large intestinal administration of the radiolabeled MBO 1. FIG. 4 illustrates the concentration of the MBO 1 equivalents in plasma, indicating that the oligonucleotide was absorbed in a time- and concentration-dependent fashion. Significant accumulation of oligonucleotide- derived radioactivity was observed in various tissues. FIG. 5 illustrates the concentration of MBO 1 equivalents in selected tissues, including kidney, liver, spleen, bone marrow, lymph node, and brain, 4 hr after administration. As can be seen in FIGS. 6B and 6C, HPLC analysis revealed both intact and degraded forms of MBO 1 in kidney, but the majority of the radioactivity in the liver and kidneys was associated with the intact form of MBO 1. Gel electrophoresis also revealed the majority of the extracted radioactivity in these samples was associated with the intact form of MBO 1 (data not shown) . No significant degraded products were detected in large intestine for up to 4 hr after administration. Approximately 4 to 14% of administered MBO 1 was absorbed within 4 hr in the anesthetized animals, depending on the dose levels. In separate studies, similar results were obtained following rectal administration of PS-oligonucleotide and MBO 2. At 10 mg/kg, PS-oligonucleotide had a 4-hr absorption ratio of 8.74% of the administered dose, and MBO 2 had a ratio of 6.6% of the administered dose (data not shown) . Previous studies described in Zhang et al . ( Clin . Chem. (1995) 41:863-873), demonstrated that, following oral administration, PS-oligonucleotides could be well absorbed through the gastrointestinal wall, but were extensively degraded in the liver; little intact PS-oligonucleotides were available, therefore, in the systemic tissues. Rectal delivery- avoids the first-pass effect in the liver. Following large intestine administration, PS-oligonucleotide was well absorbed largely in the intact form and was less extensively degraded in other tissues. Furthermore, because absorption rates were estimated in anesthetized rats, the actual bioavailability of colorectal oligonucleotides may be underestimated. These studies represent the first reports on the bioavailability of antisense oligonucleotides following colorectal administration in experimental animals. They show that, following large intestine administration: 1) PS-oligonucleotide and end-modified oligonucleotides were stable in the large intestinal lumen; 2) they were absorbed through the large intestine wall; 3) the absorbed oligonucleotide-derived radioactivity was widely distributed to various tissues with a pattern similar to that seen following i.v. administration; and 4) radioactivity in tissues such as liver and kidneys was associated with intact oligonucleotide as well as metabolites . Thus, using the method of the invention, successful absorption of oligonucleotides was accomplished through the intestinal tract and distributed throughout the body. Intact oligonucleotides were detected in plasma and various tissues. These results demonstrate that colorectal administration is a potential means for delivery of oligonucleotides as therapeutic agents. These results also demonstrate that synthetic oligonucleotides can be introduced in intact form into a mammal, and that such an oligonucleotides can be found in intact form at least four hours after colorectal administration in intact form in systemic plasma and in other organs and tissues. The following examples illustrate the preferred modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results. EXAMPLES 1. Synthesis and Analysis of Oligonucleotide Hybrid 25-mer phosphorothioate-linked oligonucleotides having SEQ ID NO:l and 11 and containing 2 ' -0-methyl ribonucleotide 3 ' and 5 ' sequences and a deoxyribonucleotide interior was synthesized, purified, and analyzed as follows. Unmodified phosphorothioate deoxynucleosides were synthesized on CPG on a 5-6 μmole scale on an automated synthesizer (model 8700, Millipore, Bedford, MA) using the H-phosphonate approach described in U.S. Patent No. 5,149,798. Deoxynucleoside H-phosphonates were obtained from Millipore (Bedford, MA). 2 ' -O-methyl ribonucleotide H-phosphonates or phosphorothioates were synthesized by standard procedures (see, e.g., "Protocols for Oligonucleotides and Analogs" in Meth. Mol. Biol. (1993) volume 20) or commercially obtained (e.g., from Glenn Research, Sterling, VA and Clontech, Palo Alto, CA) . Segments of oligonucleotides containing 2 ' -O-methyl nucleoside (s) were assembled by using 2 ' -O-methyl ribonucleoside H-phosphonates or phosphorothioates for the desired cycles. Similarly, segments of oligonucleotides containing deoxyribonucleosides were assembled by using deoxynucleoside H-phosphonates for the desired cycles. After assembly, CPG bound oligonucleotide H-phosphonate was oxidized with sulfur to generate the phosphorothioate linkage. Oligonucleotides were then deprotected in concentrated NH 4 OH at 40°C for 48 hours. Crude oligonucleotide (about 500 A 260 units) was analyzed on reverse low pressure chromatography on a C 18 reversed phase medium. The DMT group was removed by treatment with 80% aqueous acetic acid, then the oligonucleotides were dialyzed against distilled water and lyophilized. A 2 ' -O-methyl end-protected oligonucleotide shown in FIG. 2 and having SEQ ID NO: 16 was prepared as described in Agrawal and Tang (Antisense Res . Dev. (1992)2:261-66), Padmapriya et al . (Antisense Res . Dev. (1994) 4:185-199), Zhang et al . (Biochem. Pharmacol . (1995) 50:545-556; and Zhang et al . ( J. Pharm . Exp . Ther . (1996) 278:971-979). 2. Radioactive Labelling of Oligonucleotide To obtain 35 S-labelled oligonucleotide, synthesis was carried out in two steps. The first 19 nucleotides of the sequence SEQ ID NO:l) from its 3 ' -end were assembled using the β-cyanoethyl- phosphoramidite approach (see, Beaucage in Protocols for Oligonucleotides and Analogs (Agrawal, ed. ) , Humana Press, (1993), pp. 33-61) . The last six nucleotides were assembled using the H-phosphonate approach (see, Froehler in Protocols for Oligonucleotides and Analogs (Agrawal, ed.) Humana Press, 1993, pp. 63-80). Controlled pore glass (CPG) support-bound oligonucleotide (30 mg of CPG; approximately 1 μM) containing five H- phosphonate linkage was oxidized with 35 S 8 (4 mCi, 1 Ci/mg, Amersham; 1 Ci = 37 GBq) in 60 ml carbon disulfide/pyridine/triethylamine (10:10:1). The oxidation reaction was performed at room temperature for 1 hr with occasional shaking. Then 2 μl, 5 μl, and 200 μl of 5% cold sulfur ( 32 S 8 ) in same solvent mixture was added every 30 rain to complete the oxidation. The solution was removed and the CPG support was washed with carbon disulfide/pyridine/ triethylamine (10:10:1) (3 x 500 μl) and with acetonitrile (3 x 700 μl) . The product was deprotected in concentrated ammonium hydroxide (55°C, 14 hr) and evaporated. The resultant product was purified by polyacrylamide gel electrophoresis (20% polyacrylamide containing 7 M urea) . The desired band was excised under UV shadowing and the PS-oligonucleotide was extracted from the gel and desalted with a Sep-Pak C18 cartridge (Waters) and Sephadex G-15 column. The yield was 20 A 260 units (600 μg; specific activity, 1 μCi/μg) . 3. Animals and Drug Treatment Male Sprague-Dawley rats (150-200 g, Harlan Laboratories, Indianapolis, IN) were used in the study. The animals were fed with commercial diet and water ad libitum for 1 week prior to the study. After each animal was anesthetized using pentobarbital, an incision was made on the lower part of the abdomen to expose the large intestine. The colon was cut open at the position of 0.5 cm to caecum. The large intestine contents were washed out using 30 ml of physiological saline (0.9% NaCl) at 37°C. After the anus was ligated, unlabelled and [ 35 S] -labelled oligonucleotides dissolved in physiological saline (0.9% NaCl) at designated concentrations were injected into the large intestine through the cut that was ligated after drug administration. The abdomen was then closed and the body temperature was maintained at 38 ± 0.5°C by means of a heat lamp. Oligonucleotides were administered to rats at four dose levels, i.e., 3.3, 10, 30, and 90 mg/kg (3 rats per dose level) . Blood samples were collected in heparinized tubes from animals at the various times, i.e., 1, 2, 3, and 4 hrs . Plasma was separated by centrifugation. At 4 hr after drug administration, animals were euthanized by exsanguination under sodium pentobarbital anesthesia. Following euthanasia, all tissue/organs were collected, immediately blotted on Whatman No. 1 filter paper, trimmed of extraneous fat or connective tissue, emptied and cleaned of all contents, and individually weighed prior to quantitation of oligonucleotide-derived radioactivity. Biological samples were analyzed by determination of total radioactivity, HPLC, and PAGE analysis using the methods described above. 4. Total Radioactivity Measurements The total radioactivities in tissues and body fluids were determined by liquid scintillation spectrometry (LS 6000TA, Beckman, Irvine, CA) . In brief, biological fluids (plasma, 50-100 μl; urine, 50-100 μl) were mixed with 6 ml scintillation solvent (Budget-Solve, RPI, Mt . Prospect, IL) to determine total radioactivity. Feces were ground and weighed prior to being homogenized in a 9-fold volume of 0.9% NaCl saline. An aliquot of the homogenate (100 μl) was mixed with solubilizer (TS- 2, RPI, Mt . Prospect, IL) and then with scintillation solvent (6 ml) to permit quantitation of total radioactivity. Following their removal, tissues were immediately blotted on Whatman No. 1 filter paper and weighed prior to being homogenized in 0.9% NaCl saline (3-5 ml per gram of wet weight) . The resulting homogenate (100 μl) was mixed with solubilizer (TS-2, RPI, Mt . Prospect, IL) and then with scintillation solvent (6 ml) to determine total radioactivity. The volume of 0.9% NaCl saline added to each tissue sample was recorded. The homogenized tissues/organs were kept frozen at <-70°C until the use for further analysis. 5. HPLC Analysis The radioactivity in urine was analyzed by paired-ion HPLC using a modification of the method described essentially by Sands et al . (Λfol. Pharm. (1994) 45:932-943). Urine samples were centrifuged and passed through a 0.2-μm Aero filter (Gelman, Ann Arbor, MI) prior to analysis. Hybrid oligonucleotide and metabolites in plasma samples were extracted using the above methods in sample preparation for PAGE. A Microsorb MV-C4 column (Rainin Instruments, Woburn, MA) was employed in HPLC using a Hewlett Packard 1050 HPLC with a quaternary pump for gradient making . Mobile phase included two buffers; Buffer A was 5 mM-A reagent (Waters Co., Bedford, MA) in water and Buffer B was 4:1 (v/v) Acetonitrile (Fisher) /water . The column was eluted at a flow rate of 1.5 ml/min, using the following gradient: (1) 0-4 min, 0% buffer B; (2) 4- 15 min 0-35% Buffer B; and (3) 15-70 min 35%-80% Buffer B. The column was equilibrated with Buffer A for at least 30 min prior to the next run. By using a RediFrac fraction collector (Pharmacia LKB Biotechnology, Piscataway, NJ) , 1-min fractions (1.5 ml) were collected and mixed with 5 ml scintillation solvent to determine radioactivity in each fraction. 6. Gel electrophoresis. Polyacrylamide gel electrophoresis (PAGE) of the extracted oligonucleotides was carried out using methods previously described (Agrawal et al . (1995) Biochem . Pharmacol . 50:571-576; Zhang et al . (1995) Biochem . Pharmacol . 49:929-939; Zhang et al . (1995) Biochem . Pharmacol . 50:571-576; and Zhang et al . (1996) J. Pharm . Exp . Ther . 278:971-979). Plasma and tissue homogenates were incubated with proteinase K (2 mg/ml) in extraction buffer (0.5% SDS/10 mM NaCl/20 mM Tris-HCl, pH 7.6/10 mM EDTA) for 1 hr at 60°C. The samples were then extracted twice with phenol/chloroform (1:1, v/v) and once with chloroform. After ethanol precipitation, the extracts were analyzed by electrophoresis in 20% polyacrylamide gels containing 7 M urea. Urine samples were filtered, desalted, and then analyzed by PAGE. The gels were fixed in 10% acetic acid/ 10% methanol solution and then dried before autoradiography . EQUIVALENTS Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims. SEQUENCE LISTING ;i) GENERAL INFORMATION: (i) APPLICANT: AGRAWAL, SUDHIR ZHANG , RUIWEN (ii) TITLE OF INVENTION: DOWN-REGULARION OF GENE EXPRESSION BY COLORECTAL ADMINISTRATION OF SYNTHETIC OLIOGNUCLEOTIDES (iii) NUMBER OF SEQUENCES: 21 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: HALE AND DORR LLP (B) STREET: 60 State Street (C) CITY: Boston (D) STATE: MA (E) COUNTRY: United States of America (F) ZIP: 02109 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS /MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US98/ (B) FILING DATE: 12-MAR-1998 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/846,417 (B) FILING DATE: 30 -APR-1997 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/040,738 (B) FILING DATE: 12-MAR-1997 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Kerner , Ann-Louise (B) REGISTRATION NUMBER: 33,523 (C) REFERENCE/DOCKET NUMBER: HYZ-067 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 526-6000 (B) TELEFAX: (617) 526-5000 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid [iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : CTCTCGCACC CATCTCTCTC CTTCU 25 (2) INFORMATION FOR SEQ ID NO : 2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : CTCTCGCACC CATCTCTCTC CTUCU 25 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : CTCTCGCACC CATCTCTCTC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 : CTCTCGCACC CATCTCUCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : CTCTCGCACC CAUCUCUCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : CUCUCGCACC CAUCUCUCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : CTCTCGCACC CATCTCTCTC CTTCU 25 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8 : CUCUCGCACC CATCTCTCTC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 : CUCUCGCACC CATCTCUCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10 CUCUCGCACC CAUCUCUCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: CUCUCGCACC CATCTCTCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: CUCUCGCACC CAUCTCTCTC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13 CUCUCGCACC CATCTCTCTC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: CUCTCGCACC CAUCUCUCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: CUCTCGCACC CATCTCTCUC CUUCU 25 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: CTCTCGCACC CATCTCTCTC CTTC 24 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: CTCTCGCACC CATCTCTCTC CTTCT 25 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: CUCTCGCACC CATCTCTCTC CTTCT 25 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: CUCUCGCACC CATCTCTCTC CTTCT 25 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: CUCUCGCACC CAUCUCTCTC CTTCT 25 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: CUCUCGCACC CAUCUCUCUC CTTCT 25

Claims: What is claimed is: 1. A method of down-regulating the expression of a gene in an animal, the method comprising the step of colorectally administering a pharmaceutical formulation comprising an oligonucleotide having non-phosphodiester internucleotide linkages and being complementary to the gene in a pharmaceutically acceptable carrier, the oligonucleotide inhibiting the expression of a product of the gene, thereby down-regulating the expression of the gene. 2. The method of claim 1, wherein the oligonucleotide comprises at least one 2 ' - substituted ribonucleotide or methylphosphonate deoxynucleotide . 3. The method of claim 2 wherein the oligonucleotide has 3 ' and 5 ' termini and the 2 ' - substituted ribonucleotide is at the 3' terminus. 4. The method of claim 3 wherein the oligonucleotide further comprises at least one 2 ' - substituted ribonucleotide at the 5' terminus. 5. The method of claim 2 wherein all of the nucleotides in the oligonucleotide are 2 ' - substituted ribonucleotides. 6. The method of claim 2 wherein the 2'- substituted ribonucleotide is a 2 ' -O-alkyl- ribonucleotide . 7. The method of claim 1 wherein the oligonucleotide comprises at least one deoxyribonucleotide . 8. The method of claim 7 wherein the oligonucleotide comprises a region of at least four contiguous deoxyribonucleotides capable of activating RNase H activity. 9. The method of claim 1 wherein the oligonucleotide comprises an internucleotide linkage selected from the group consisting of alkylphosphonates , phosphorothioates , phosphorodithioates , alkylphosphonothioates , phosphoramidates, phosphoramidites, phosphate esters, carbamates, carbonates, phosphate triesters, acetamidate, and carboxymethyl esters. 10. The method of claim 9 wherein essentially all of the nucleotides are linked via phosphorothioate or phosphorodithioate internucleotide linkages . 11. The method of claim 1 wherein the oligonucleotide is further modified. 12. The method of claim 1 wherein the oligonucleotide is complementary to a gene of a virus, pathogenic organism, or a cellular gene. 13. The method of claim 12 wherein the oligonucleotide is complementary to a gene of a virus involved in a disease selected from the group consisting of AIDS, oral and genital herpes, papilloma warts, influenza, foot and mouth disease, yellow fever, chicken pox, shingles, adult T-cell leukemia, Burkitt ' s lymphoma, nasopharyngeal carcinoma, and hepatitis. 14. The method of claim 1 wherein the oligonucleotide is complementary to a gene encoding a protein associated with Alzheimer's disease . 15. The method of claim 1 wherein the oligonucleotide is complementary to a gene encoding a protein in a parasite causing a parasitic disease selected from the group consisting of amebiasis, Chagas ' disease, toxoplasmosis, pneumocytosis, giardiasis, cryptoporidiosis, trichomoniasis, malaria, ascariasis, filariasis, trichinosis, schistosomiasis infections. 16. The method of claim 1 wherein the oligonucleotide is complementary to an HIV gene and comprises about 15 to 26 nucleotides linked by phosphorothioate internucleotide linkages, at least one of the nucleotides at the 3 ' terminus being a 2 ' -substituted ribonucleotide or a methylphosphonate deoxynucleotide, and at least four nucleotides being contiguous deoxyribonucleotides . 17. The method of claim 2 wherein the oligonucleotide has 3 ' and 5 ' termini and at least one methylphosphonate deoxynucleotide is at the 3 ' terminus and the 5 ' terminus . 18. The method of claim 17 wherein the oligonucleotide has at least two methylphosphonate deoxynucleotides at the 3 ' terminus and at the 5 ' terminus . 19. The method of claim 18, wherein the oligonucleotide further comprises phosphorothioate internucleotide linkages . 20. A method for introducing an intact oligonucleotide into a mammal, the method comprising the step of colorectally administering an oligonucleotide of about 15 to 25 nucleotides, and comprising non-phosphodiester internucleotide linkages, wherein the oligonucleotide is present in intact form in the systemic plasma of the mammal at least four hours following administration. 21. The method of claim 20, wherein the oligonucleotide is end-protected. 22. The method of claim 20, wherein the oligonucleotide has 3 ' and 5 ' termini and comprises at least one 2 ' -O-methyl-ribonucleotide or methylphosphonate deoxynucleotide at the 3 ' terminus , the 5 ' terminus , or the 3 ' and 5 ' termini . 23. The method of claim 21, wherein the end- protected oligonucleotide comprises at least two 2 ' -O-methyl-ribonucleotides or methylphosphonate deoxynucleotides at each terminus. 24. The method of claim 21, wherein the end- protected oligonucleotide comprises at least two 2 ' -O-methyl-ribonucleotides at each terminus and further comprises phosphorothioate internucleoside linkages . 25. The method of claim 21, wherein the end- protected oligonucleotide comprises at least two methylphosphonate deoxynucleotides at each terminus and further comprises phosphorothioate internucleotide linkages. 26. The method of claim 21, wherein the end- protected oligonucleotide comprises four methylphosphonate deoxynucleotides at each terminus . 27. The method of claim 22, wherein the oligonucleotide comprises at least two 2 ' -O- methyl-ribonucleotides or methylphosphonate deoxynucleotides at each terminus . 28. The method of claim 22, wherein the oligonucleotide comprises at least two 2 ' -O- methyl-ribonucleotides at each terminus and further comprises phosphorothioate internucleoside linkages . 29. The method of claim 22, wherein the oligonucleotide comprises at least two methylphosphonate deoxynucleotides at each terminus and further comprises phosphorothioate internucleotide linkages. 30. The method of claim 22, wherein the oligonucleotide comprises four methylphosphonate deoxynucleotides at each terminus. 31. The method of claim 20, wherein the oligonucleotide comprises phosphorothioate internucleotide linkages.

Inventors: AGRAWAL SUDHIR, ZHANG RUIWEN, AGRAWAL, SUDHIR, ZHANG, RUIWEN
Applicants: HYBRIDON INC, HYBRIDON, INC.
Application year: 1998
Main classification: A61K31
IPC codes: A61K9, A61K31, A61K48, A61P31, A61P35